INDICATION

ERLEADA^® is indicated in adult men for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Medical castration with gonadotropin releasing hormone analogue (GnRHa) should be continued during ERLEADA^® treatment in patients not surgically castrated.

Reference:
1. ERLEADA^® (apalutamide) summary of product characteristics. Janssen, 2018.

CP-142079